Brazil's Anvisa Suspends Sales of Clobutinol-Based Cough Syrups
Mmarket.newsApr 29, 20260AI-Synthesized
The Quick Take
- Anvisa (Brazil's health regulator) suspended sales of all cough syrups containing clobutinol over cardiac arrhythmia risk
- No market price movement data available; pharmaceutical stocks with clobutinol exposure face potential downside pressure
- No analyst or institutional response cited in available coverage; single-source report from InfoMoney
- Affected pharma companies must halt distribution; regulatory review and potential product reformulation expected next
- Global pharma firms selling clobutinol-based products in Latin America or Asia may face similar regulatory scrutiny
Synthesized from 1 source โ full coverage, sentiment breakdown, and forward signals below.
AI Indicators
Market Intelligence Panel
Sentiment
Bearish๐ข 0โช 0๐ด 1
Coverage
live1
source covering this story
T1: 0T2: 1T3: 0
Live Price
BMFBOVESPA:IBOV๐ India / Asia Angle
Clobutinol has been used in cough preparations in several Asian markets; Brazil's Anvisa action may prompt India's CDSCO and other Asian regulators to review or re-examine the safety status of clobutinol-containing products in their jurisdictions.
๐ Ripple Effects
- โธBrazilian pharma stocks with clobutinol-based product lines โ bearish pressure due to forced sales suspension and potential liability
- โธGeneric drug manufacturers supplying clobutinol API (active pharmaceutical ingredient) globally โ bearish on reduced demand outlook
- โธBroader OTC cough-and-cold segment in Brazil โ bearish near-term as consumer confidence in affected product category may decline
๐ญ What to Watch Next
PRO- โธAnvisa's official publication of the suspension resolution โ monitor Anvisa's Diรกrio Oficial notices for full list of affected brand names and manufacturers
- โธResponse from Brazilian pharma companies (e.g., EMS, Hypera Pharma) โ watch for investor communications or product recall announcements within 48โ72 hours
- โธInternational regulatory follow-through โ monitor WHO, India's CDSCO, and EU EMA for any advisory or safety communication referencing clobutinol post-Anvisa action
Market news synthesis. Not financial advice. Sources cited above.
Timeline
1 publishers ยท 1 time windowsHow the Story Spread
All Sources
1 publisher covering this story
โ Tier 2: 1
AI synthesis of every source listed below. Tier 1 = wire services (AP, Reuters via wire, Bloomberg, official central banks). Tier 2 = major financial publishers. Tier 3 = niche / specialist outlets. Click any card to read the original article.
Get the Daily Briefing
Pre-market analysis every morning at 6am ET. Free.